ArticleJournal of anaesthesiology, clinical pharmacology
Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis.
Article in Journal of anaesthesiology, clinical pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Genetic regulation of cell type-specific chromatin accessibility contributes to migraine etiology.The journal of headache and pain · 2026Article
- Innovative strategies for diabetic peripheral neuropathy: From clinical management to emerging bioengineering solutions.Bioactive materials · 2026Review
- Spinal Metastases of the Vertebrae: Three Main Categories of Pain.Life (Basel, Switzerland) · 2024Review
- Light-Inducible Activation of TrkA for Probing Chronic Pain in Mice.ACS chemical biology · 2024Article
- Communicating pain: emerging axonal signaling in peripheral neuropathic pain.Frontiers in neuroanatomy · 2024Review
- Various Doses of Tanezumab in the Management of Chronic Low Back Pain (CLBP): A Pooled Analysis of 4,514 Patients.Cureus · 2023Review
- Neuropathic pain; what we know and what we should do about it.Frontiers in pain research (Lausanne, Switzerland) · 2023Review
- Up-Regulation of ProBDNF/p75Journal of inflammation research · 2023Article
- A High Body Mass Index and the Vacuum Phenomenon Upregulate Pain-Related Molecules in Human Degenerated Intervertebral Discs.International journal of molecular sciences · 2022Article
- Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis.European journal of pain (London, England) · 2022Article
- ProNGF/NGF Modulates Autophagy and Apoptosis through PI3K/Akt/mTOR and ERK Signaling Pathways following Cerebral Ischemia-Reperfusion in Rats.Oxidative medicine and cellular longevity · 2022Article
- Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials.Therapeutic advances in musculoskeletal disease · 2022Article
- Nerve Growth Factor as an Ocular Therapy: Applications, Challenges, and Future Directions.Seminars in ophthalmology · 2021Article
- Neurophysiological Mechanisms Related to Pain Management in Bone Tumors.Current neuropharmacology · 2021Article
- Peripheral Voltage-Gated Cation Channels in Neuropathic Pain and Their Potential as Therapeutic Targets.Frontiers in pain research (Lausanne, Switzerland) · 2021Review
- Article
- Role of Nerve Growth Factor in Orofacial Pain.Journal of pain research · 2020Review
- Bone Pain in Cancer Patients: Mechanisms and Current Treatment.International journal of molecular sciences · 2019Review
- Nerves in Bone: Evolving Concepts in Pain and Anabolism.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019Review
- Crosstalk Between Sensory Nerves and Cancer in Bone.Current osteoporosis reports · 2018Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, nerve growth factor (NGF) and the NGF receptor have become potential therapeutic targets in the treatment of acute and chronic pain states. NGF is a neurotrophin involved in regulating the function of sensory and sympathetic neurons during development. Numerous pain states have been linked to elevated levels of NGF and its role in increasing the perception of pain. Tanezumab, a recombinant humanized monoclonal antibody (IgG), was developed to target NGF, binding both circulating and local tissue NGF preventing interaction with the tropomyosin-related kinase-A and p75 receptors. Recent clinical studies with tanezumab in different patient populations to date, including osteoarthritis, low back pain, and diabetic peripheral neuropathy, demonstrate efficacy with few side effects, including transient arthralgias, paresthesias, hypoesthesia, and rarely, osteonecrosis. Anti-NGF antibodies are a novel therapy in pain management and have shown promise in the treatment of certain pain conditions, which at present are poorly treated. Tanezumab offers an exciting new class of analgesics that has the potential to change the treatment of pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.